I wanted to wait several weeks to see if what was occurring with our largest & most consistent RXers was an anomaly or a trend. The reason why I am posting this now is because it is certainly a trend. We are seeing top writers drying up since the co-pay card change that took away the $15 override. With our largest commercial plans not covering Airsupra, providers are pulling back their usage. The worst part is, the patients who were on Airsupra and were leveraging the $15 override, now cannot so they are back on albuterol. This is obviously impacting Trx's. My question to all is: Is anyone else seeing this in their territories? I can't imagine we are the only ones.
Dont worry, they will all be replaced by other failed stong women from other failing companies like Solventum, Baxter, mimedx to name a few. That's the new model.